Henning Robert J
Department of Environmental & Occupational Health, College of Public Health, University of South Florida & the James A Haley Hospital, Tampa, FL 33612-3805, USA.
Future Cardiol. 2018 Mar;14(2):181-192. doi: 10.2217/fca-2017-0072. Epub 2018 Feb 6.
One out of every two men and one out of every three women greater than the age of 40 will experience an acute myocardial infarction (AMI) at some time during their lifetime. As more patients survive their AMIs, the incidence of congestive heart failure (CHF) is increasing. 6 million people in the USA have ischemic cardiomyopathies and CHF. The search for new and innovative treatments for patients with AMI and CHF has led to investigations and use of human embryonic stem cells, cardiac stem/progenitor cells, bone marrow-derived mononuclear cells and mesenchymal stem cells for treatment of these heart conditions. This paper reviews current investigations with human embryonic, cardiac, bone marrow and mesenchymal stem cells, and also stem cell paracrine factors and exosomes.
每两名40岁以上男性中就有一人、每三名40岁以上女性中就有一人在其一生中的某个时候会经历急性心肌梗死(AMI)。随着越来越多的患者在急性心肌梗死后存活下来,充血性心力衰竭(CHF)的发病率正在上升。美国有600万人患有缺血性心肌病和充血性心力衰竭。对急性心肌梗死和充血性心力衰竭患者新的创新治疗方法的探索,已促使人们对人类胚胎干细胞、心脏干/祖细胞、骨髓来源的单核细胞和间充质干细胞进行研究并用于治疗这些心脏疾病。本文综述了目前对人类胚胎干细胞、心脏干细胞、骨髓干细胞和间充质干细胞的研究,以及干细胞旁分泌因子和外泌体的研究。